On September 25, 2023, Alliance Global Partners took the initiative to cover Vaccitech (NASDAQ:VACC) and bestowed it with a Buy rating, along with an announced price target of $12. Vaccitech, a prominent clinical-stage biopharmaceutical company, is dedicated to the development of immunotherapies and vaccines for both infectious diseases and cancer. Notably, the company has made remarkable strides in the field by collaborating with the prestigious University of Oxford and AstraZeneca to create a COVID-19 vaccine candidate. This candidate has exhibited promising results in clinical trials and has consequently received emergency use authorization in multiple countries
https://beststocks.com/alliance-global-partners-initiates-coverage-o/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.